Literature DB >> 12898127

The effects of systemically administered taurine and N-pivaloyltaurine on striatal extracellular dopamine and taurine in freely moving rats.

J Salimäki1, G Scriba, T P Piepponen, N Rautolahti, L Ahtee.   

Abstract

The second most abundant cerebral amino acid, taurine, is widely consumed in the so-called "energy drinks". Therefore, its possible actions on the brain are of great interest. In the present experiments taurine was given intraperitoneally to rats in order to study if it can be administered systemically in large enough amounts to alter cerebral dopaminergic transmission or to induce hypothermia. In addition, the effects of subcutaneously administered lipophilic taurine analogue, N-pivaloyltaurine, were studied. The extracellular striatal taurine and dopamine concentrations were estimated using in vivo microdialysis in awake and freely moving rats, and the rectal temperatures were measured. Taurine at the total dose of 45 mmol/kg i.p. led to a maximally 8-fold increased striatal extracellular taurine concentration, induced a long-lasting hypothermia, and significantly reduced the striatal extracellular dopamine concentration. The latter effect was strengthened by co-treatment with reuptake inhibitor nomifensine. N-pivaloyltaurine (15 mmol/kg in total, s.c.) only slightly elevated the striatal extracellular taurine concentration, failed to alter the rectal temperature, and in contrast to taurine somewhat elevated the striatal extracellular dopamine concentration suggesting a different mechanism or locus of action from that of taurine. Finally, our experiments using brain microdialysis confirmed the earlier findings that taurine is slowly eliminated from the brain. The results clearly indicate that systemically given taurine enters the brain in concentrations that induce pharmacological effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898127     DOI: 10.1007/s00210-003-0776-6

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  41 in total

1.  Characterisation of methylphenidate and nomifensine induced dopamine release in rat striatum using in vivo brain microdialysis.

Authors:  S P Butcher; J Liptrot; G W Aburthnott
Journal:  Neurosci Lett       Date:  1991-01-28       Impact factor: 3.046

2.  [Isotonic beverages, "energy" and "power" drinks].

Authors:  S Greubel
Journal:  Med Monatsschr Pharm       Date:  1998-11

3.  Locally infused taurine, GABA and homotaurine alter differently the striatal extracellular concentrations of dopamine and its metabolites in rats.

Authors:  M Ruotsalainen; M Majasaari; J Salimäki; L Ahtee
Journal:  Amino Acids       Date:  1998       Impact factor: 3.520

4.  The depression of brain stem neurones by taurine and its interaction with strychnine and bicuculline.

Authors:  H L Haas; L Hösli
Journal:  Brain Res       Date:  1973-03-30       Impact factor: 3.252

5.  Changes in the extracellular profiles of neuroactive amino acids in the rat striatum at the asymptomatic stage of hepatic failure.

Authors:  W Hilgier; M Zielińska; H D Borkowska; R Gadamski; M Walski; S S Oja; P Saransaari; J Albrecht
Journal:  J Neurosci Res       Date:  1999-04-01       Impact factor: 4.164

6.  Central dopaminergic neurons: effects of alterations in impulse flow on the accumulation of dihydroxyphenylacetic acid.

Authors:  R H Roth; L C Murrin; J R Walters
Journal:  Eur J Pharmacol       Date:  1976-03       Impact factor: 4.432

7.  Taurine acts on a subclass of GABAA receptors in mammalian brain in vitro.

Authors:  M H Bureau; R W Olsen
Journal:  Eur J Pharmacol       Date:  1991-05-25       Impact factor: 4.432

8.  Homotaurine and muscimol mimic taurine and GABA effects on muscle tone and temperature regulation.

Authors:  G P Sgaragli; V Carlà; M Magnani; A Giotti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-11       Impact factor: 3.000

9.  Dopamine uptake is differentially regulated in rat striatum and nucleus accumbens.

Authors:  C Missale; L Castelletti; S Govoni; P F Spano; M Trabucchi; I Hanbauer
Journal:  J Neurochem       Date:  1985-07       Impact factor: 5.372

10.  Regional distribution and extracellular levels of amino acids in rat central nervous system.

Authors:  U Tossman; G Jonsson; U Ungerstedt
Journal:  Acta Physiol Scand       Date:  1986-08
View more
  7 in total

Review 1.  Taurine, caffeine, and energy drinks: Reviewing the risks to the adolescent brain.

Authors:  Christine Perdan Curran; Cecile A Marczinski
Journal:  Birth Defects Res       Date:  2017-12-01       Impact factor: 2.344

Review 2.  Structural, chemical and biological aspects of antioxidants for strategies against metal and metalloid exposure.

Authors:  Swaran J S Flora
Journal:  Oxid Med Cell Longev       Date:  2009 Sep-Oct       Impact factor: 6.543

3.  Neuroprotective Mechanisms of Taurine against Ischemic Stroke.

Authors:  Janet Menzie; Howard Prentice; Jang-Yen Wu
Journal:  Brain Sci       Date:  2013-06-03

4.  Taurine and Epidermal Growth Factor Belong to the Signature of First-Episode Psychosis.

Authors:  Kati Koido; Jürgen Innos; Liina Haring; Mihkel Zilmer; Aigar Ottas; Eero Vasar
Journal:  Front Neurosci       Date:  2016-07-15       Impact factor: 4.677

Review 5.  Taurine and its analogs in neurological disorders: Focus on therapeutic potential and molecular mechanisms.

Authors:  Md Jakaria; Shofiul Azam; Md Ezazul Haque; Song-Hee Jo; Md Sahab Uddin; In-Su Kim; Dong-Kug Choi
Journal:  Redox Biol       Date:  2019-05-21       Impact factor: 11.799

6.  Sulfur-containing therapeutics in the treatment of Alzheimer's disease.

Authors:  Haizhou Zhu; Venkateshwara Dronamraju; Wei Xie; Swati S More
Journal:  Med Chem Res       Date:  2021-01-15       Impact factor: 1.965

7.  Advances in drug design based on the amino Acid approach: taurine analogues for the treatment of CNS diseases.

Authors:  Man Chin Chung; Pedro Malatesta; Priscila Longhin Bosquesi; Paulo Renato Yamasaki; Jean Leandro Dos Santos; Ednir Oliveira Vizioli
Journal:  Pharmaceuticals (Basel)       Date:  2012-10-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.